Pharmaceutical

Novartis eyes first-line status for its radionucleotide therapy Lutathera

The Phase III trial of Luthathera as a first-line therapy showed improved progression-free survival in treating GEP-NETs.

Sep 25, 2023 - 20:00
Novartis eyes first-line status for its radionucleotide therapy Lutathera
The Phase III trial of Luthathera as a first-line therapy showed improved progression-free survival in treating GEP-NETs.
Read the original article

Tags:

Previous Article

Signal: AbbVie ends multi-million dollar cancer drug deal with I-Mab

Next Article

China’s NMPA approves Henlius’ oesophageal cancer therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Mankind Pharma acquires Bharat Serums and Vaccines for $1.6bn

Mankind Pharma acquires Bharat Serums and Vaccines for ...

Jul 28, 2024

Monash University team to receive funds for prostate cancer therapy

Monash University team to receive funds for prostate ca...

Nov 20, 2023

Genentech review of Tessier-Lavigne paper finds no evidence of fraud — but hints at a different misconduct case

Genentech review of Tessier-Lavigne paper finds no evid...

Apr 7, 2023